...
机译:吉他珠单抗奥佐米星联合恩西他滨和柔红霉素在老年复发或难治性急性髓性白血病患者中的一期试验:日本成人白血病研究组(JALSG)-GML208研究
Division of Hematology, First Department of Internal Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan;
Department of Hematology and Oncology, Nagoya City West Medical Center, Nagoya, Japan;
Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan;
Division of Hematology, Fujioka General Hospital, Fujioka, Japan;
Division of Hematology, First Department of Internal Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan;
Division of Hematology, First Department of Internal Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan;
Department of Clinical Laboratory Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan;
Hematology Division, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan;
Department of Internal Medicine 3, Oncology Center;
Acute myeloid leukemia; Elderly; Gemtuzumab ozogamicin; Chemotherapy;
机译:吉他珠单抗奥佐米星联合恩西他滨和柔红霉素在老年复发或难治性急性髓性白血病患者中的一期试验:日本成人白血病研究组(JALSG)-GML208研究
机译:吉妥单抗ozogamicin在强化联合化疗中用于复发或难治的成人急性髓细胞白血病(AML)的I期试验:日本成人白血病研究组(JALSG)-AML206研究。
机译:吉妥单抗ozogamicin在强化联合化疗中用于复发或难治性成人急性髓细胞性白血病(AML)的I期试验:日本成人白血病研究组(JALSG)‐AML206研究
机译:计算源自骨髓移植后急性髓性白血病患者复发风险的细胞学图像标志物
机译:根据2017年日本成人白血病研究组(JALSG)AML201研究治疗的成人急性髓性白血病患者的遗传学预测,根据2017 ELN风险分层进行预后分析
机译:I / II期研究:Gemtuzumab ozogamicin联合伏立诺他和阿扎胞苷治疗老年复发或难治性急性髓细胞白血病患者
机译:阶段I试验Gemtuzumab ozogamicin在密集的组合化疗复发或难治性成人急性髓性白血病(AML):日本成人白血病研究组(JALSG)-AML206研究